| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Nektar rises as analyst evaluates pipeline | | 3 | Yahoo-USA |
| 22.05.
| Possible Bullish Inside Day Candle Pattern Detected for Nektar Therapeutics | | - | SmarTrend |
| 14.05.
| Post Earnings Update: Nektar Therapeutics Has Sunk 5.1% Lower in Past Week | | 1 | SmarTrend |
| 04.05.
| Nektar Therapeutics Has Returned 25.3% Since SmarTrend Recommendation | | - | SmarTrend |
| 03.05.
| Nektar Therapeutics Beats Up on Analysts Yet Again | | 1 | Motley Fool |
| 03.05.
| Nektar Therapeutics Loss Widens, Misses Estimate | | 59 | AFX News |
| WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) Wednesday reported
first-quarter net loss of $41 million or $0.36 per hare, compared to net loss of
$36 million or $0.33 per share last...
Mehr lesen zu:
Nektar Therapeutics Loss Widens, Misses Estimate | |
| 02.05.
| Nektar Therapeutics Reports Financial Results for the First Quarter of 2012 | | 11 | PR Newswire |
| SAN FRANCISCO, May 2, 2012 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2012.
Cash, cash equivalents, and investments...
Mehr lesen zu:
Nektar Therapeutics Reports Financial Results for the First Quarter of 2012 | |
| 25.04.
| Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets | | 8 | PR Newswire |
| SAN FRANCISCO, April 25, 2012 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, after the...
Mehr lesen zu:
Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets | |
| 20.04.
| Uptrend Call Working As Nektar Therapeutics Stock Rises 33.8% | | 1 | SmarTrend |
| 10.04.
| Nektar to Host Investor and Analyst R&D Day in New York City | | 7 | PR Newswire |
| SAN FRANCISCO, April 10, 2012 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April 16...
Mehr lesen zu:
Nektar to Host Investor and Analyst R&D Day in New York City | |
| 02.04.
| Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain | | 29 | PR Newswire |
| SAN FRANCISCO, April 2, 2012 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics...
Mehr lesen zu:
Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain | |
| 28.03.
| Nektar Says Affymax Reveals FDA Approval Of OMONTYS Injection | | 59 | AFX News |
| WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) reported that its partner
Affymax, Inc. announced that the U.S. Food and Drug Administration, or FDA, has
approved OMONTYS (peginesatide)...
Mehr lesen zu:
Nektar Says Affymax Reveals FDA Approval Of OMONTYS Injection | |
| 28.03.
| Nektar (NKTR) Reports Partner Affymax (AFFY) Gets FDA Approval for Anemia Treatment OMONTYS | | - | StreetInsider.com |
| 28.03.
| Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis | | 9 | PR Newswire |
| SAN FRANCISCO, March 28, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Mehr lesen zu:
Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis | |
| 20.03.
| Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay | | 29 | PR Newswire |
| SAN FRANCISCO, March 20, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company is consolidating its U.S.-based research scientists at the company's...
Mehr lesen zu:
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay | |
| 03.03.
| Nektar Therapeutics Announces Webcast of Presentation at the 32nd Annual Cowen and Company Healthcare Conference in Boston | | 75 | PR Newswire |
| SAN FRANCISCO, March 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will webcast its presentation at the 32nd Annual Cowen and Company Healthcare Conference to...
Mehr lesen zu:
Nektar Therapeutics Announces Webcast of Presentation at the 32nd Annual Cowen and Company Healthcare Conference in Boston | |
| 29.02.
| Nektar Therapeutics Q4 Loss Widens | | 48 | AFX News |
| WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) Wednesday reported
fourth-quarter net loss of $37.5 million or $0.33 per share, compared to $22.6
million or $0.24 per share last year.On...
Mehr lesen zu:
Nektar Therapeutics Q4 Loss Widens | |
| 29.02.
| Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results | | 38 | PR Newswire |
| SAN FRANCISCO, Feb. 29, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2011.
Cash, cash equivalents...
Mehr lesen zu:
Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results | |
| 29.02.
| Nektar Therapeutics To Sell Royalties For CIMZIA And MIRCERA To Royalty Pharma | | 32 | AFX News |
| WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) Wednesday announced that
it has entered into an agreement with Royalty Pharma, wherein Royalty Pharma
will buy the royalties on future sales...
Mehr lesen zu:
Nektar Therapeutics To Sell Royalties For CIMZIA And MIRCERA To Royalty Pharma | |
| 29.02.
| Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million | | 67 | PR Newswire |
| SAN FRANCISCO, Feb. 29, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under...
Mehr lesen zu:
Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million | |
